Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  The Oncologist

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1634/theoncologist.2010-0129PMID 20798195PMCID PMC3228037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

  2011cited by this paper
• Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

  2010cited by this paper
• A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned.

  2010cited by this paper
• Chemotherapy and radiotherapy: cryptic anticancer vaccines.

  2010cited by this paper
• A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

  2010cited by this paper
• Cancer Statistics, 2009

  2010cited by this paper
• Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

  2009cited by this paper
• A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.

  2009cited by this paper
• Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

  2009cited by this paper
• How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.

  2009cited by this paper
• Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancer

  2009cited by this paper
• Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

  2009cited by this paper
• Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies.

  2009cited by this paper
• A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.

  2009cited by this paper
• Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

  2008cited by this paper
• Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer

  2008cited by this paper
• Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.

  2008cited by this paper
• Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement

  2008cited by this paper
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008cited by this paper
• Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

  2008cited by this paper
• Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design

  2008cited by this paper
• Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer

  2008cited by this paper
• Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial

  2008cited by this paper
• The anticancer immune response: indispensable for therapeutic success?

  2008cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Cancer Vaccines: Moving Beyond Current Paradigms

  2007cited by this paper
• Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

  2007cited by this paper
• Future directions in tumor immunotherapy: CTLA4 blockade

  2007cited by this paper
• A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?

  2007cited by this paper
• Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC).

  2006cited by this paper
• Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma

  2006cited by this paper
• RECIST revisited: a review of validation studies on tumour assessment.

  2006cited by this paper
• Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

  2006cited by this paper
• Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

  2006cited by this paper
• Androgen deprivation therapy for prostate cancer.

  2005cited by this paper
• Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

  2005cited by this paper
• Induction of an Antigen Cascade by Diversified Subcutaneous/Intratumoral Vaccination Is Associated with Antitumor Responses

  2005cited by this paper
• Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy

  2005cited by this paper
• Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

  2005cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes.

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial

  2004cited by this paper
• Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

  2003cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• Technology evaluation: APC-8015, Dendreon.

  2002cited by this paper
• Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

  2001cited by this paper
• Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Current Treatment Approaches

  1987cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• Parrondo's paradox in tumor ecosystems: Adaptive therapy strategies to delay the development of drug resistance.

  2025cites this paper
• Reduced recurrence of prostate cancer with novel autologous cancer vaccine (FK- PC101) post-prostatectomy: long-term results from a single-center phase 1/2 study

  2025cites this paper
• A phase 2 study of GI-6207 in patients with recurrent medullary thyroid cancer.

  2025cites this paper
• The landscape of genitourinary cancer vaccines: clinical advances and future opportunities.

  2025cites this paper
• Current Trends and Innovative Approaches in Cancer Immunotherapy

  2024cites this paper
• Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy.

  2024cites this paper
• Imaging‐Based Efficacy Evaluation of Cancer Immunotherapy in Engineered Tumor Platforms and Tumor Organoids

  2024cites this paper
• Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer

  2024cites this paper
• Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer

  2023cites this paper
• Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine

  2023cites this paper
• Vaccines as treatments for prostate cancer

  2023cites this paper
• Biomarkers and experimental models for cancer immunology investigation

  2023cites this paper
• Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities

  2023cites this paper
• Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.

  2023cites this paper
• Probiotic Complex Feed Additive against LL/2 Lung Cancer in Mice

  2021cites this paper
• Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations

  2021cites this paper
• Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens.

  2020cites this paper
• Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T

  2020cites this paper
• Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy

  2020cites this paper
• The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer.

  2020cites this paper
• Imaging of tumour response to immunotherapy

  2020cites this paper
• Obstacles in the Development of Therapeutic Cancer Vaccines

  2019cites this paper
• Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

  2019cites this paper
• Mouse Models for Cancer Immunotherapy Research.

  2018cites this paper
• 19F-MRI to Monitor Therapeutic Cell Migration and Distribution

  2018cites this paper
• Improving immune–vascular crosstalk for cancer immunotherapy

  2018cites this paper
• RESEARCH ARTICLE A CRITIQUE ON CANCER VACCINE.

  2018cites this paper
• Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.

  2018cites this paper
• Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

  2018cites this paper
• Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma

  2018cites this paper
• The Winds of Change: Emerging Therapeutics in Prostate Cancer.

  2018cites this paper
• Therapeutic cancer vaccines.

  2017cites this paper
• Immuno-Oncology: The Third Paradigm in Early Drug Development

  2017cites this paper
• Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment

  2017cites this paper
• Personalized peptide vaccines and their relation to other therapies in urological cancer

  2017cites this paper
• Dendritic cells based immunotherapy.

  2017cites this paper
• Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.

  2017cites this paper
• Design and synthesis of multivalent glycoconjugates for anti-cancer immunotherapy

  2017cites this paper
• Prostate cancer immunotherapy: the path forward

  2017cites this paper
• DNA vaccines for prostate cancer.

  2017cites this paper
• Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy

  2016cites this paper
• Developing immunotherapy strategies in the treatment of prostate cancer

  2016cites this paper
• Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies

  2016cites this paper
• Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives.

  2016cites this paper
• Immunotherapy for prostate cancer: False promises or true hope?

  2016cites this paper
• Maintenance monotherapy with Gemcitabine following cisplatin-based primary combination chemotherapy in surgically treated advanced urothelial carcinoma: A matched-pair single institution analysis.

  2016cites this paper
• Immune Therapy.

  2016cites this paper
• TCR diversity – a universal cancer immunotherapy biomarker?

  2016cites this paper
• The evolving role of immunotherapy in prostate cancer

  2016cites this paper
• Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines

  2016cites this paper
• TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer

  2016cites this paper
• Preclinical and clinical development of DNA vaccines for prostate cancer.

  2016cites this paper
• Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects.

  2016cites this paper
• Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine

  2015cites this paper
• Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

  2015cites this paper
• Dendritic Cell-Based Vaccine Efficacy: Aiming for Hot Spots

  2015cites this paper
• A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.

  2015cites this paper
• Immunotherapeutic approaches in prostate cancer: combinations and clinical integration.

  2015cites this paper
• Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment

  2015cites this paper
• Dendritic cell-based vaccine research against cancer

  2015cites this paper
• A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

  2015cites this paper
• U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

  2015cites this paper
• Clinically feasible approaches to potentiating cancer cell-based immunotherapies

  2015cites this paper
• Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.

  2015cites this paper
• Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.

  2015cites this paper
• Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome

  2015cites this paper
• Improving drug delivery to solid tumors: priming the tumor microenvironment.

  2015cites this paper
• Sipuleucel-T for the Treatment of Patients With Metastatic Castrate-resistant Prostate Cancer: Considerations for Clinical Practice.

  2015cites this paper
• Advances in the understanding of cancer immunotherapy

  2015cites this paper
• Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T

  2014cites this paper
• The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

  2014cites this paper
• Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications

  2014cites this paper
• (R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment.

  2014cites this paper
• Immunotherapy prospects in the treatment of lung cancer and mesothelioma.

  2014cites this paper
• Clinical use of dendritic cells for cancer therapy.

  2014cites this paper
• Harnessing the immune system to cure cancer

  2014cites this paper
• Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances

  2014cites this paper
• Therapeutic cancer vaccines.

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014cites this paper
• TRICOM Poxviral-Based Vaccines for the Treatment of Cancer

  2014cites this paper
• Nuts and Bolts of Cancer Immunotherapy

  2014cites this paper
• Poxviral-based vaccine elicits immunologic responses in prostate cancer patients

  2014cites this paper
• Immune-based therapies for childhood cancer

  2014cites this paper
• TWO Therapeutic Cancer Vaccines

  2014cites this paper
• Molecular insights into the development of T cell-based immunotherapy for prostate cancer

  2014cites this paper
• A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T

  2014cites this paper
• Ipilimumab in prostate cancer

  2013cites this paper
• Recent advances revolutionize treatment of metastatic prostate cancer.

  2013cites this paper
• Vaccine Therapy and Integration with Other Modalities

  2013cites this paper
• From diagnosis to managing advanced disease

  2013cites this paper
• Chapter 20 – Recombinant TRICOM-based Therapeutic Cancer Vaccines: Lessons Learned

  2013cites this paper
• Recombinant TRICOM-based Therapeutic Cancer Vaccines

  2013cites this paper
• Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies

  2013cites this paper
• Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome

  2013cites this paper
• Sipuleucel-T (Provenge).

  2013cites this paper
• Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?

  2013cites this paper
• Therapeutic vaccines

  2013cites this paper
• Oncolytic vaccines

  2013cites this paper
• The changing landscape in the treatment of metastatic castration-resistant prostate cancer

  2013cites this paper
• Demystifying Immunotherapy in Prostate Cancer: Understanding Current and Future Treatment Strategies

  2013cites this paper